» Articles » PMID: 6794084

The Effect of 6-hydroxydopamine on the Antinociceptive Action of Oxotremorine

Overview
Specialty Pharmacology
Date 1981 Jan 1
PMID 6794084
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Mice received intraventricular 6-hydroxydopamine (6-OHDA) to deplete brain noradrenaline (NA) and dopamine (DA). 6-OHDA reduced the reaction time of mice to nociceptive stimulus (hot plate) and attenuated the antinociceptive action of oxotremorine. The administration of 6-OHDA to desipramine treated mice prevented both the loss of cerebral NA and the antagonism of oxotremorine's antinociceptive action. The administration of 6-OHDA to pargyline-treated mice increased the depletion of cerebral DA, but the antagonism of oxotremorine's antinociceptive action persisted. Catecholamines were measured in mouse brain at intervals from 1 h to 3 days after administration of 6-OHDA. DA levels failed to correlate with either the reduction in the hot plate reaction time or the antagonism of oxotremorine analgesia, whereas these effects were usually accompanied by a loss of brain NA. Centrally acting DA agonists failed to restore oxotremorine's antinociceptive action in 6-OHDA-treated mice. Intraventricular administration of the acetylcholine synthesis inhibitor triethylcholine to mice did not effect the antinociceptive action of oxotremorine. It is concluded that the antinociceptive action of oxotremorine in mice is initiated by stimulation of muscarinic receptors and involves noradrenergic neurones.

Citing Articles

Selective brain noradrenaline depletion induced by the neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP 4) does not prevent the memory facilitation induced by a muscarinic agonist in mice.

Introini I, Baratti C, Huygens P Psychopharmacology (Berl). 1984; 82(1-2):107-12.

PMID: 6420819 DOI: 10.1007/BF00426391.


Possible cholinergic-dopaminergic link in memory facilitation induced by oxotremorine in mice.

Baratti C, Introini I, Huygens P, Gusovsky F Psychopharmacology (Berl). 1983; 80(2):161-5.

PMID: 6136061 DOI: 10.1007/BF00427961.

References
1.
Bloom F, Algeri S, Groppetti A, Revuelta A, Costa E . Lesions of central norepinephrine terminals with 6-OH-dopamine: biochemistry and fine structure. Science. 1969; 166(3910):1284-6. DOI: 10.1126/science.166.3910.1284. View

2.
Nakamura K, Kuntzman R, Maggio A, Conney A . Decrease in morphine's analgesic action and increase in its cataleptic action by 6-hydroxydopamine injected bilaterally into caudate and putamen areas; partial restoration by L-DOPA plus decarboxylase inhibition. Neuropharmacology. 1973; 12(12):1153-60. DOI: 10.1016/0028-3908(73)90072-5. View

3.
Slater P . Effect of 6-hydroxydopamine on some actions of tremorine and oxotremorine. Eur J Pharmacol. 1974; 25(2):130-7. DOI: 10.1016/0014-2999(74)90040-5. View

4.
BARAR F, MADAN B . Tremorine-oxotremorine-induced tremor, hypothermia and analgesia, and physostigmine toxicity, in mice after pretreatment with beta-adrenoceptor antagonists. J Pharm Pharmacol. 1976; 28(4):286-9. DOI: 10.1111/j.2042-7158.1976.tb04154.x. View

5.
Evetts K, Iversen L . Effects of protriptyline on the depletion of catecholamines induced by 6-hydroxydopamine in the brain of the rat. J Pharm Pharmacol. 1970; 22(7):540-3. DOI: 10.1111/j.2042-7158.1970.tb10564.x. View